## BEAM: Beam Therapeutics Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 8.6% in mid entry zone (4.0-10.0%), top 7% cross-sectional ranking. Caution: MRS_5 (-3.1%) diverging from MRS_20, watch for reversal. Outperforming sector by 13.1%. Caution: momentum weakening (-6.0% MRS).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($23.00)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Beam Therapeutics Reports Updated Data from BEACON Phase**
- Source: GlobeNewswire | 20251207T045240 | Bullish | Relevance: 99%
- Beam Therapeutics announced updated data from its BEACON Phase 1/2 clinical trial for ristoglogene autogetemcel (risto-cel) in sickle cell disease (SCD) patients. The data highlights the therapy's durable efficacy, including significant HbF induction and HbS reduction, along with a safety profile consistent with busulfan conditioning and autologous hematopoietic stem cell transplantation. Patients showed efficient cell collection, rapid engraftment, and no severe vaso-occlusive crises post-engraftment.

**2. Beam Therapeutics stock rises on promising sickle cell therapy data**
- Source: Investing.com | 20251208T084900 | Bullish | Relevance: 99%
-  Beam Therapeutics Inc. (NASDAQ:BEAM) saw its stock rise after presenting updated positive data from its BEACON Phase 1/2 clinical trial for ristoglogene autogetemcel (risto-cel) in sickle cell disease. The data showed durable hemoglobin F induction and hemoglobin S reduction, with a favorable safety profile and efficient cell collection. The company is progressing towards a regulatory filing for the treatment.

**3. Beam Therapeutics edges higher after new sickle cell therapy results**
- Source: MSN | 20251208T161004 | Bullish | Relevance: 97%
- Beam Therapeutics (BEAM) saw its shares rise after presenting new data for its sickle cell disease therapy, BEAM-101, at the American Society of Hematology meeting. Updated results from the Phase 1/2 clinical trial showed an almost complete elimination of sickle cells and improved total hemoglobin levels, particularly fetal hemoglobin. The company also announced plans to initiate a global Phase 3 study in mid-2025.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-24 | Evercore ISI Gr | $35 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-24 | Evercore ISI Gr | init | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.02M) |
| Sells | 5 ($0.65M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 70.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 2 |

**Top Holders:**
- FMR, LLC: 11.5% (-9.8%)
- ARK Investment Manag: 10.9% (+24.8%)
- Farallon Capital Man: 9.9% (+0.5%)
- Vanguard Group Inc: 9.1% (-4.7%)
- Blackrock Inc.: 8.0% (+1.8%)

### Key Risks

1. High beta (2.22) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Valuation stretched: PEG 7.0x requires aggressive growth execution.
3. High short interest (22.8%, 8.2 days to cover): squeeze risk or crowded bearish bet.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 7.04 signals overvaluation risk, limited margin of safety. Balance sheet: strong liquidity (6.0x), low leverage (D/E 0.36). Institutional flow bullish (6 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.7B |
| Beta | 2.22 |
| 52W Range | $13.53 - $35.25 |
| Short Interest | 22.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 7.04 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 deteriorating from 14.6% to 8.6% (-6.0% in 5 days), indicating relative weakness vs NASDAQ. Currently in upper STRENGTH zone (4.0-10.0%), cross-sectional ranking at 92nd percentile. MRS_5 (-3.1%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 10.8% shows strong absolute momentum above own 20MA. Outperforming sector by 13.1pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.51), confirming momentum. RSI neutral at 57.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 8.59% (CS: 93) | Strong |
| RSI_14 | 56.8 | Neutral |
| MACD Histogram | 0.51 | Bullish |
| vs SMA20 | 1.108x | Above |
| vs SMA50 | 1.061x | Above |
| vs SMA200 | 1.261x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $26.48
- **Stop Loss:** $23.00 (13.1% risk)
- **Target:** $31.70 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 86
- **Position Value:** $2,277.28
- **Portfolio %:** 2.28%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-24 (Est: $-1.12)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.01 | $-1.10 | -8.9% |
| 2025Q2 | $-1.09 | $-1.00 | +8.4% |
| 2025Q1 | $-1.17 | $-1.24 | -5.9% |
| 2024Q4 | $-1.22 | $-1.09 | +10.3% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*